Burkholderia pseudomallei acquired ceftazidime resistance due to gene duplication and amplification

Int J Antimicrob Agents. 2019 May;53(5):582-588. doi: 10.1016/j.ijantimicag.2019.01.003. Epub 2019 Jan 9.

Abstract

Ceftazidime (CAZ) is the antibiotic of choice for the treatment of Burkholderia pseudomallei infection (melioidosis). The chromosomally-encoded PenA β-lactamase possesses weak cephalosporinase activity. The wild-type penA gene confers clinically significant CAZ resistance only when overexpressed due to a promoter mutation, transcriptional antitermination or by gene duplication and amplification (GDA). Here we characterise a reversible 33-kb GDA event involving wild-type penA in a CAZ-resistant B. pseudomallei clinical isolate from Thailand. We show that duplication arises from exchanges between short (<10 bp) chromosomal sequences, which in this example consist of 4-bp repeats flanked by 3-bp inverted repeats. GDA involving β-lactamases may be a common CAZ resistance mechanism in B. pseudomallei.

Keywords: Amplification; Burkholderia pseudomallei; Ceftazidime; Gene duplication; Resistance; β-Lactamase.

MeSH terms

  • Anti-Bacterial Agents / pharmacology*
  • Burkholderia pseudomallei / drug effects*
  • Burkholderia pseudomallei / enzymology
  • Burkholderia pseudomallei / genetics
  • Ceftazidime / pharmacology*
  • DNA, Bacterial / genetics
  • Drug Resistance, Bacterial*
  • Gene Amplification*
  • Gene Duplication*
  • Humans
  • Melioidosis / microbiology
  • Thailand
  • beta-Lactamases / genetics*

Substances

  • Anti-Bacterial Agents
  • DNA, Bacterial
  • Ceftazidime
  • beta-Lactamases